>

WEBINARS

RSS
>

MEETINGS / EVENTS

RSS
>

FDA MEDWATCH ALERTS

RSS

January 12, 2012

Respironics, Inc. Trilogy 100 Ventilators: Class I Recall - Device May Stop Delivering Therapy to Patient

Summary:

FDA notified health care professionals of the Class 1 recall of this product due to a manufacturing issue can stop delivering therapy to the patient. Part of the blower that circulates air and other gases through the ventilator may move out of position and cause the device to alarm.  Failure to respond could result in the potential for harm or death of a ventilator-dependent patient.

January 12, 2012

Bedford Laboratories Vecuronium Bromide And Polymyxin B For Injection USP For Injection: Recall - Glass Particles

Summary:

Bedford Laboratories issued guidance on the nationwide voluntary product recalls originally issued on August 2, 2011. The recalls were initiated after the discovery of a visible glass particle in a limited number of vials within the lots listed.

January 09, 2012

Endo Pharmaceuticals Opiate Products by Novartis Consumer Health: Public Health Advisory - Potential Safety Risk

Summary:

FDA is advising health care professionals and patients of a potential problem with opiate products manufactured and packaged for Endo Pharmaceuticals by Novartis Consumer Health at its Lincoln, Nebraska manufacturing site.

>

ASA FEATURED PRODUCT

Self-Education and Evaluation (SEE) Program

SKU: 30701-12CE

... Read more »

Single Copies, Member Price: $300

2012 Medicare Conversion Factors

Thursday, January 05, 2012

Recent legislative action has provided for a zero percent update to the Medicare conversion factor for services provided from January 1 through February 29, 2012.  The final rule on the Medicare Fee Schedule indicated that there would be an increase in the conversion factor for budget neutrality and this change will also be effective January 1, 2012.  The budget neutrality increase is due to CMS adoption of the RVS Update Committee recommendations for misvalued codes.  The anesthesia conversion factor also increased due to the on-going transition to new data to determine practice expense values.  As you may recall, data from the Physician Practice Information Survey (PPIS) is being transitioned into the fee schedule over a four year period.  This updated data is a result of ASA and other’s work on the PPIS.

The 2011 unadjusted Anesthesia conversion factor was $21.0515.  The January – February 2012 Anesthesia conversion factor will be $21.4089  (an increase of 1.67%).

Please click here for locale specific conversion factors.

The 2011 RBRVS conversion factor was $33.9764.  The January to February 2012 RBRVS conversion factor will be $34.0376 (an increase of 0.18%).

« Back to Washington Alerts